- Home
- GOSS vs QNST Comparison
GOSS vs QNST Comparison
Compare GOSS & QNST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GOSS | QNST |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.8M | 792.3M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GOSS | QNST |
|---|---|---|
| Price | $3.57 | $14.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $8.60 | ★ $25.75 |
| AVG Volume (30 Days) | ★ 3.3M | 583.2K |
| Earning Date | 11-05-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $44,051,000.00 | ★ $1,100,345,000.00 |
| Revenue This Year | N/A | $11.73 |
| Revenue Next Year | $6.41 | $9.82 |
| P/E Ratio | ★ N/A | $83.69 |
| Revenue Growth | N/A | ★ 43.12 |
| 52 Week Low | $0.76 | $12.98 |
| 52 Week High | $3.87 | $25.50 |
Technical Indicators
Market Signals| Indicator | GOSS | QNST |
|---|---|---|
| Relative Strength Index (RSI) | 56.81 | 49.94 |
| Support Level | $3.53 | $14.43 |
| Resistance Level | $3.87 | $15.08 |
| Average True Range (ATR) | 0.24 | 0.49 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 51.96 | 39.58 |
Price Performance
Historical ComparisonAbout GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About QNST QuinStreet Inc.
QuinStreet Inc focuses on marketplaces and technologies for the financial services and home services industries. It delivers measurable and cost-effective marketing results to its clients, in the form of qualified inquiries such as clicks, leads, calls, applications, or customers. It generates revenue by delivering measurable online marketing results to the clients. Its products and services are Customer Acquisition, QuinStreet Rating Platform (QRP), and CloudControlMedia. Geographically, it operates in United States and Internationally, of which maximum revenue is derived from United States.